These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. Blanco F; Barreiro P; Ryan P; Vispo E; Martín-Carbonero L; Tuma P; Labarga P; Medrano J; González-Lahoz J; Soriano V J Viral Hepat; 2011 Jan; 18(1):11-6. PubMed ID: 20088890 [TBL] [Abstract][Full Text] [Related]
3. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D; J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942 [TBL] [Abstract][Full Text] [Related]
4. [A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection]. Zheng YH; Yang X; Chang WH Hunan Yi Ke Da Xue Xue Bao; 2003 Aug; 28(4):390. PubMed ID: 14653126 [No Abstract] [Full Text] [Related]
5. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES). Lowe SH; Hassink EA; van Eck-Smit BL; Borleffs JC; Lange JM; Reiss P HIV Clin Trials; 2007; 8(5):337-44. PubMed ID: 17956835 [TBL] [Abstract][Full Text] [Related]
6. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team. Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512 [TBL] [Abstract][Full Text] [Related]
7. Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection. Ioannou GN; Bryson CL; Weiss NS; Boyko EJ Eur J Gastroenterol Hepatol; 2015 May; 27(5):577-84. PubMed ID: 25769096 [TBL] [Abstract][Full Text] [Related]
8. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030 [TBL] [Abstract][Full Text] [Related]
9. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. Cotte L; Bénet T; Billioud C; Miailhes P; Scoazec JY; Ferry T; Brochier C; Boibieux A; Vanhems P; Chevallier M; Zoulim F J Hepatol; 2011 Mar; 54(3):489-96. PubMed ID: 21056493 [TBL] [Abstract][Full Text] [Related]
10. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082 [TBL] [Abstract][Full Text] [Related]
13. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. Macías J; Castellano V; Merchante N; Palacios RB; Mira JA; Sáez C; García-García JA; Lozano F; Gómez-Mateos JM; Pineda JA AIDS; 2004 Mar; 18(5):767-74. PubMed ID: 15075511 [TBL] [Abstract][Full Text] [Related]
14. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Kovari H; Ledergerber B; Peter U; Flepp M; Jost J; Schmid P; Calmy A; Mueller NJ; Muellhaupt B; Weber R; Clin Infect Dis; 2009 Aug; 49(4):626-35. PubMed ID: 19589079 [TBL] [Abstract][Full Text] [Related]
15. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. Kooij KW; Wit FW; van Zoest RA; Schouten J; Kootstra NA; van Vugt M; Prins M; Reiss P; van der Valk M; AIDS; 2016 Jul; 30(11):1771-80. PubMed ID: 27088320 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients. Raffi F; Reliquet V; Auger S; Besnier JM; Chennebault JM; Billaud E; Michelet C; Perre P; Lafeuillade A; May T; Billaudel S AIDS; 1998 Oct; 12(15):1999-2005. PubMed ID: 9814868 [TBL] [Abstract][Full Text] [Related]
17. Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. Pollard RB; Peterson D; Hardy D; Pottage J; Murphy RL; Gathe J; Beall G; Rutkievicz V; Reynolds L; Cross AP; Dunkle LM J Acquir Immune Defic Syndr; 1999 Sep; 22(1):39-48. PubMed ID: 10534145 [TBL] [Abstract][Full Text] [Related]
18. Liver Fibrosis Assessment in a Cohort of Greek HIV Mono-Infected Patients by Non-Invasive Biomarkers. Androutsakos T; Schina M; Pouliakis A; Kontos A; Sipsas N; Hatzis G Curr HIV Res; 2019; 17(3):173-182. PubMed ID: 31549590 [TBL] [Abstract][Full Text] [Related]
19. Noncirrhotic portal hypertension in HIV infection. Vispo E; Morello J; Rodriguez-Novoa S; Soriano V Curr Opin Infect Dis; 2011 Feb; 24(1):12-8. PubMed ID: 21157331 [TBL] [Abstract][Full Text] [Related]
20. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. Smith CJ; Olsen CH; Mocroft A; Viard JP; Staszewski S; Panos G; Staub T; Blaxhult A; Vetter N; Lundgren JD AIDS; 2008 Jan; 22(1):47-56. PubMed ID: 18090391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]